TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00758758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Hedrocel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Hedrocel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Hedrocel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Allograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Allograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Autograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Autograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Implantation of Autograft
Study: NCT00083772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
Study: NCT04733313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guıded quadratus lumborum block
Description: Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guıded quadratus lumborum block
Description: Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
Study: NCT03089619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human-Spongiosa
Description: after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: collacone®
Description: after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
Study: NCT02856529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General session
Description: A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
Study: NCT04402671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-cross-linked porcine skin collagen membrane
Description: non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glutaraldehyde cross-linked bovine collagen membrane
Description: glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
Study: NCT00710164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)
Description: 14 days of XSCR capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days of Placebo
Study: NCT03049111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Der f
Description: Inhalation of Der f in mild asthmatics who are sensitive to Der f.
Study: NCT02333773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
Study: NCT04859686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation.
Study: NCT02546635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl
Description: AX-024.HCl will be administered as per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-024.HCl
Description: AX-024.HCl will be administered as per the protocol defined frequency and dose level
Study: NCT04508140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Biopsy
Description: In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Biopsy
Description: In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 with pembrolizumab
Description: BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 with pembrolizumab
Description: BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.
Study: NCT00554112

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise
Study: NCT01284530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM XR
Description: Equivalent TDD in XR form, QD, Day 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM XR
Description: Equivalent TDD in XR form, QD, Day 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM XR
Description: Equivalent TDD in XR form, QD, Day 1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM XR
Description: Equivalent TDD in XR form, QD, Day 1-14
Study: NCT02747654

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genotype
Description: Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
Study: NCT00068783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03562637

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adagloxad simolenin combined with OBI-821
Description: In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globo H IHC Assay
Description: The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Globo H IHC Assay
Description: The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
Study: NCT01456390

Intervention type: DEVICE
Group type: OTHER
Intervention: iStent and iStent supra
Description: Implantation of two iStent devices and one iStent supra device
Study: NCT03686826

Intervention type: PROCEDURE
Intervention: Acquisition of MEP und SSEP
Description: Acquisition of MEP und SSEP at two different time points within 1 to 30 days

Intervention type: PROCEDURE
Intervention: Acquisition of MEP und SSEP
Description: Acquisition of MEP und SSEP at two different time points within 1 to 30 days
Study: NCT01016704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
Study: NCT04148833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE-Paclitaxel
Description: LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LDE-Placebo
Description: LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
Study: NCT03029130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter extension
Description: Foley transurethral catheter placed to allow continuous drainage of urine.
Study: NCT02810340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted MCV-5
Description: Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM), and 125 μg Al3+adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-Adjuvanted MCV-5
Description: Contains 5 μg each of N. meningitidis A, C, Y, W, and X polysaccharides, 2.42 mg sucrose, 0.40 mg sodium citrate, 0.098 mg tris (trometamol), 7.8 to 33.4 μg tetanus toxoid, and 11.7 to 50.1 μg cross reactive material of diphtheria toxin (CRM).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra®
Description: Menactra® vaccine was a clear to slightly turbid solution supplied in a 0.5 mL single dose vial. Each 0.5 mL dose of vaccine was formulated in sodium phosphate buffered isotonic sodium chloride solution to contain four mcg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 μg of diphtheria toxoid protein carrier and residual amounts of formaldehyde of less than 2.66 μg (0.000532%), by calculation.
Study: NCT02528266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Capping Device
Study: NCT03004157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation
Description: CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation
Description: CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiopulmonary resuscitation
Description: CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
Study: NCT00464386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: measure glucose levels on burn patients
Study: NCT03546049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided percutaneous biliary drainage
Description: Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage
Description: Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm.
Study: NCT00052520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transplantation
Study: NCT00974766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
Study: NCT00052520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: staining method
Description: Correlative studies
Study: NCT03117205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of Kinesio Taping®
Description: The technique was applied following the methods described in the original method for patellofemoral instability

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping® placebo application
Description: Simulation of the application of the Kinesio Taping® technique.
Study: NCT03700398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: first OE
Description: optical enhancement(OE)，a kind of electron straining endoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: first WLI
Description: the routine in the clinical practice
Study: NCT02864524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulative and Massage Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Study: NCT05819437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy program
Description: Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C.
Study: NCT00973050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg Tablet
Study: NCT00974766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
Study: NCT00973050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Casodex®
Description: 50 mg Tabelt
Study: NCT02333773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
Study: NCT00101725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: crofelemer
Study: NCT04516811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) plus standard of care (SOC)
Description: A single unit of approximately 200-250 mL of CCP that contains anti-SARS-CoV-2 collected by plasmapheresis from a volunteer who recovered from COVID19 with SOC as determined by local practice and guidelines.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC) plus placebo
Description: A single unit of 200 mL normal saline with SOC as determined by local practice and guidelines
Study: NCT04543344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: recifercept powder for solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recifercept
Description: recifercept powder for solution for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection
Study: NCT03422978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single dose dexmedetomidine administered over 60 seconds post-induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single dose dexmedetomidine administered over 60 seconds post-induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Single dose dexmedetomidine administered over 60 seconds post-induction.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Single dose normal saline administered over 60 seconds post-induction.
Study: NCT02396030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 50% - 1g/h
Description: Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50% - 2g/h
Description: Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
Study: NCT04599452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cell regimen group
Description: 10 patients with recurrent refractory elderly AML were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15.
Study: NCT04655313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151 cream 0.3%
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Study: NCT01330355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besivance
Description: Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
Study: NCT01528124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3025876
Description: Given as a subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as a subcutaneous injection
Study: NCT03836664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: Timolol is a clear solution supplied in a plastic ophthalmic dispenser.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline solution that will be supplied in container matched to Timolol container.
Study: NCT00743405

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1034702
Description: Oral or liquid

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1034702
Description: Oral or liquid

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK1034702

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To match GSK1034702
Study: NCT04300855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunphenon
Description: The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01916967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
Study: NCT03393910

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Pelvic Exam
Description: The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam.